Concepedia

Yuping Dong

YD

Statistics

Publications

8

Citations

866

H-Index

8

Active since

2008

Affiliations

Bristol-Myers Squibb (United States)(Current)

Medical University of Białystok

University of California, San Francisco

Bellvitge University Hospital

Amsterdam UMC Location University of Amsterdam

Yuping Dong is an author at Bristol-Myers Squibb (United States) specializing in pharmacy, pharmacotherapy, and pharmacology.

ORCID

Publications per year

2008–2023

8

Publications

8

Evinacumab in Patients with Refractory Hypercholesterolemia

Robert S. Rosenson, Lesley Burgess, Christoph Ebenbichler et al. · New England Journal of Medicine · 2020 · 294 citations · Full text

, , +17

Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant Recipients

R M Ferguson, J.M. Grinyó, Flavio Vincenti et al. · American Journal of Transplantation · 2010 · 207 citations · Full text

, , +17

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

Dirk Blom, Mariko Harada‐Shiba, Paolo Rubba et al. · Journal of the American College of Cardiology · 2020 · 165 citations · Full text

, , +17

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert et al. · Clinical Cancer Research · 2023 · 81 citations · Full text

, , +17

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study

Josep M. Grinyó, Josefina Alberú, F.L.C. Contieri et al. · Transplant International · 2012 · 53 citations · Full text

, , +14

1–5 of 8